

## Special Issue

# Tumor Suppressor and Innate Immunity

### Message from the Guest Editors

The COVID pandemic made the vaccine a buzzword, harnessing the power of one's immunity to fight infections. Although the vaccine is a century-old research area with remarkable successful examples of eradicating infectious diseases such as polio, there are more research opportunities in the field, awaiting more discoveries. As with any other research field, vaccine development also faces challenges. This special issue promotes vaccine research to address the major challenges for advancing the field and broadening the research scope. We believe that nucleic acid vaccines can serve as a powerful weapon against increasing viral infections. Therefore, discovering new vaccines and their possible genotoxic effects will discover more effective vaccines. Along with the development of mainstream vaccinations, we think that technological advancements provide a platform for vaccine development.

### Guest Editors

Dr. Markus Vähä-Koskela

Institute for Molecular Medicine Finland (FIMM), University of Helsinki,  
00100 Helsinki, Finland

Dr. Disha Malani

Institute for Molecular Medicine Finland (FIMM), University of Helsinki,  
00100 Helsinki, Finland

### Deadline for manuscript submissions

closed (30 November 2021)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/85799](https://mdpi.com/si/85799)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).